Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

A haematologist shares insights into the challenges of the disease and the promise of emerging treatment options.

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.

SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

He further explained he was diagnosed with a slow-growing "bone marrow cancer" called Waldenström's macroglobulinemia (WM): ...

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on ...

The "sledgehammer-like treatment" of stem cell transplants had no benefit for most mantle cell lymphoma patients, according ...

Julio Chavez, MD, MS, discusses some of the important studies and research being presented at the 2024 American Society of ...